Physician profile
Alexander Rubin
NPI 1720273915
$133,493.21
in general payments reported to CMS, 2019-2025
30 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $16K · 2021: $11K · 2022: $9,870 · 2023: $9,114 · 2024: $15K · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $3,432 · Travel and Lodging: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,020.00 |
| Food and Beverage | $3,431.79 |
| Travel and Lodging | $224.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $77,353.28 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $39,794.57 | 2019-2021 | |
| Pfizer INC. | $11,139.30 | 2019-2025 | |
| Amgen INC. | $877.88 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $609.68 | 2019-2024 | Watchman Access System, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $577.38 | 2019-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $521.05 | 2019-2024 | Mitraclip |
| Astrazeneca Pharmaceuticals LP | $357.81 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $334.14 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.47 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $321.09 | 2021-2025 | Verquvo |
| Astellas Pharma US INC | $173.10 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.23 | 2020-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $137.62 | 2021-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $134.70 | 2024 | Arcalyst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $110.38 | 2019-2021 | |
| Novo Nordisk INC | $107.13 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Edwards Lifesciences Corporation | $95.68 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Esperion Therapeutics, INC. | $84.42 | 2021-2023 | Nexletol |
| Irhythm Technologies, INC. | $58.85 | 2021-2023 | Zio Xt Patch |
| Althera Pharmaceuticals LLC | $32.86 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $30.72 | 2019 | |
| Daiichi Sankyo INC. | $24.84 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $24.35 | 2023 | Arcalyst |
| Medtronic, INC. | $23.05 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.32 | 2024 | |
| Lundbeck LLC | $17.34 | 2020 | |
| Glaxosmithkline, LLC. | $16.15 | 2025 | Shingrix, Arexvy |
| Agepha Pharma Fz LLC | $13.97 | 2024 | Lodoco |
| Atricure, INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.